Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 4/20 | 0.51 |
| ▸ | QSOX1 | O00391 | 1/20 | 0.51 |
| ▸ | RGS12 | O14924 | 1/20 | 0.51 |
| ▸ | PMM2 | O15305 | 1/20 | 0.51 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYBB | P04839 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5916661 | 0.82 | MPI (0.50) | KDM4EMEN1PKMKMT2AMETAP2 | |
| SCHEMBL10747356 | 0.82 | AURKA (0.44) | KDM4ENPC1RAB9APAX8MEN1 | |
| SCHEMBL10745420 | 0.75 | METAP2 (0.53) | KDM4EMEN1PKMKMT2AMETAP2 | |
| SCHEMBL5916801 | 0.72 | METAP2 (0.53) | KDM4EMEN1PKMKMT2AMETAP2 | |
| SCHEMBL5916571 | 0.70 | METAP2 (0.54) | KDM4EMEN1PKMKMT2AMETAP2 | |
| SCHEMBL10749275 | 0.70 | METAP2 (0.54) | KDM4EMEN1PKMKMT2AMETAP2 | |
| Ebselen SCHEMBL33829 | 0.69 | METAP2 (1.00) | KDM4EMEN1PKMKMT2AMETAP2 | |
| Ebselen SCHEMBL29370082 | 0.69 | METAP2 (1.00) | KDM4EMEN1PKMKMT2AMETAP2 | |
| Ebselen SCHEMBL4406056 | 0.69 | METAP2 (1.00) | KDM4EMEN1PKMKMT2AMETAP2 | |
| SCHEMBL5291860 | 0.69 | RAB9A (1.00) | KDM4ENPC1RAB9APAX8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2006-06-22 | — | — | US | claimed |
| EP-1541145-A1 | THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE | Institute of Materia, Chinese Academy of Medical Sciences (CN) | 2005-06-15 | — | — | EP | claimed |
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2006-06-22 | — | — | US | disclosed |
| EP-1541145-A1 | THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE | Institute of Materia, Chinese Academy of Medical Sciences (CN) | 2005-06-15 | — | — | EP | disclosed |
| US-4711961-A | Benzisoselenazolethiones and process for the treatment of various diseases in humans | A. NATTERMANN & CIE GMBH (DE) | 1987-12-08 | — | — | US | disclosed |
| US-4550168-A | Benzisoselenazolones and a process for the treatment of inflammatory diseases | A. NATTERMANN & CIE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
| EP-0100899-A2 | Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them | A. Nattermann & Cie. GmbH (DE) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | TNNI3, TNNT2, MYLK2 | KDM4E 2585/4885NPC1 1567/4885RAB9A 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.